ArticleJournal of pediatric gastroenterology and nutrition2011
Granulocyte macrophage-colony-stimulating factor autoantibodies and increased intestinal permeability in Crohn disease.
Article in Journal of pediatric gastroenterology and nutrition, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Performance of fecal S100A12 as a novel non-invasive diagnostic biomarker for pediatric inflammatory bowel disease: a systematic review and meta-analysis.Jornal de pediatriaPooled it
- Inflammatory and Immune Cytoprofiles of Active Ulcerative Colitis from Crohn's Disease-Insights from Multivariable Modeling.International journal of molecular sciences · 2026Article
- Association between serum anti-granulocyte-macrophage colony-stimulating factor autoantibodies and nintedanib-induced diarrhea in interstitial lung disease: a retrospective study.Journal of thoracic disease · 2026Article
- Postbiotic Metabolites from a 31-StrainBiology · 2026Article
- Rapid Serological Detection of Anti-GM-CSF Autoantibodies in Autoimmune Pulmonary Alveolar Proteinosis Using a Novel Immunochromatographic Test.Respirology (Carlton, Vic.) · 2026Article
- Type 17 immunity: novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells.Cellular & molecular immunology · 2024Review
- Quantification of Enteric Dysfunction in Cystic Fibrosis: Inter- and Intraindividual Variability.The Journal of pediatrics · 2024Article
- Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease.Frontiers in immunology · 2023Article
- Article
- Building a Population Representative Pediatric Biobank: Lessons Learned From the Greater Cincinnati Childhood Cohort.Frontiers in public health · 2020Article
- Pulmonary Alveolar Proteinosis with Ulcerative Colitis.Internal medicine (Tokyo, Japan) · 2018Article
- Familial Association of Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Inflammatory Bowel Disease.Journal of pediatric gastroenterology and nutrition · 2018Article
- Impaired granulocyte-macrophage colony-stimulating factor bioactivity accelerates surgical recurrence in ileal Crohn's disease.World journal of gastroenterology · 2018Article
- Maternal low intensity physical exercise prevents obesity in offspring rats exposed to early overnutrition.Scientific reports · 2017Article
- GM-CSF and the role of myeloid regulatory cells in the pathogenesis and treatment of Crohn's disease.Molecular and cellular pediatrics · 2015Article
- [Biomarkers for chronic inflammatory diseases].Zeitschrift fur Rheumatologie · 2015Review
- Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2014Review
- Increased prevalence of luminal narrowing and stricturing identified by enterography in pediatric Crohn's disease patients with elevated granulocyte-macrophage colony stimulating factor autoantibodies.Inflammatory bowel diseases · 2013Article
- The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.Inflammatory bowel diseases · 2013Review
- Paediatric Crohn disease patients with stricturing behaviour exhibit ileal granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody production and reduced neutrophil bacterial killing and GM-CSF bioactivity.Clinical and experimental immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundAlterations in intestinal permeability have been implicated in the pathogenesis of Crohn disease (CD). We have reported that granulocyte macrophage-colony-stimulating factor (GM-CSF) is required for mucosal barrier function in mice, and elevated neutralizing GM-CSF autoantibodies (Ab) are associated with stricturing ileal disease and surgery in patients with CD. We hypothesized that children with CD with elevated GM-CSF Ab would exhibit increased intestinal permeability. PATIENTS AND
methodsSubjects were divided into 3 groups: 15 with CD and high GM-CSF Ab (≥ 1.6 μg/mL, GM-CSF Ab Hi), 12 with CD and low GM-CSF Ab (<1.6 μg/mL, GM-CSF Ab Lo), and 15 healthy controls. Subjects ingested a lactulose:mannitol (L:M) solution, and urinary excretion of LM was measured by high-performance liquid chromatography. Serum GM-CSF Ab, endotoxin core Ab (EndoCAb), and lipopolysaccharide-binding protein (LBP), and fecal S100A12 were determined by enzyme-linked immunosorbent assay.
resultsThe CD groups did not vary by age, sex, disease location, or activity. Neither systemic (serum LBP) nor mucosal (fecal S100A12) inflammation differed between the CD groups. Intestinal permeability as measured by the urine L:M ratio and endotoxin exposure as measured by serum EndoCAb were increased in the GM-CSF Ab Hi group compared to the GM-CSF Ab Lo group and controls.
conclusionsPatients with CD with elevated GM-CSF Ab exhibit an increase in bowel permeability relative to patients with CD with lower levels of GM-CSF Ab in the absence of differences in systemic or intestinal inflammation. Therapies that target the mucosal barrier may be of particular benefit in this subgroup of patients with CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.